Due to unforeseen scheduling conflicts, the RASCALS Foundation regrets to announce that its 3rd Annual 5K Walk/Run has been postponed to a later date.
“Jon Imber’s Left Hand” picks up at the start of what Imber calls “my ALS summer.” It is a story about the artist and his wife, the painter Jill Hoy. The pair for decades have been key members of the Stonington and Maine painting communities. While Imber is the object of the film, Hoy is its true subject.
Why are military veterans, particularly those who served in the First Gulf War, twice as likely to get ALS when compared to the rest of the population? Since 2008, the Veterans Administration has recognized that there’s a clear link between ALS and military service, and the agency considers it to be a service-connected disability.
Study Shows Neuralstem Cells Transplanted Into Brain Significantly Improve Post-Stroke Symptoms in Rats
The researchers concluded that the NSI-566 cells are potent cell donors for transplantation therapy to treat paralysis in stroke patients
BrainStorm Cell Therapeutics, a leading developer of adult stem cell technologies for neurodegenerative diseases, announced today that it has signed a definitive agreement with the Massachusetts General Hospital (MGH) in Boston, MA to conduct a Phase II clinical trial of NurOwn™ in amyotrophic lateral sclerosis (ALS).
While the size of this study is small, the ability of the specific biomarkers used to predict ALS prognosis suggests that the approach holds promise.
Research led by King’s College London has identified a new genetic variant, located on chromosome 17, associated with sporadic amyotrophic lateral sclerosis (ALS) – the most common form of motor neurone disease (MND).
For patients with amyotrophic lateral sclerosis (ALS), the simple act of breathing is often a tough thing to do. Now, these patients have new hope, as a device has been approved by the U.S. Food and Drug Administration (FDA) that may help patients to breathe more easily without a ventilator.
Respiratory failure is one of the major complications associated with amyotrophic lateral sclerosis (ALS). The quest for alternative approaches for treating respiratory failure has led to the study, and subsequent FDA approval, of diaphragm pacing for use in ALS patients.
“We are very excited to announce the selection of IMS-088 as ImStar’s lead ALS compound. As we continue with preclinical development next year, we hope to establish IMS-088 as a safe and effective new drug candidate for ALS,” said Jean-Pierre Julien, ImStar’s chief scientific officer.